Division of Clinical Pharmacology

From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

Probing statin-associated diseases with genetics

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.

VUMC team discovers new genetic disease

Researchers at Vanderbilt University Medical Center have discovered a new genetic disease that causes a severe form of neurogenic orthostatic hypotension, a rapid drop in blood pressure upon standing that can cause fainting.

(iStock photo)

Heat for hypertension in autonomic failure

Heat therapy could offer a novel nonpharmacologic approach for treating the overnight hypertension that affects patients with autonomic failure.

Roden honored with Oscar B. Hunter Career Award in Therapeutics

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

New clue to postural tachycardia

Insight into the pathophysiology of an enigmatic and debilitating disease suggests new treatment approaches.

1 2 3 4 5 6 11